Cargando...
Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma
BACKGROUND: Primary or secondary drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) is a new challenge in the treatment of advanced non-small cell lung cancer (NSCLC). Osimertinib is a third-generation EGFR-TKI, and its efficacy and safety in NSCLC patients wit...
Gardado en:
| Publicado en: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
AME Publishing Company
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7481609/ https://ncbi.nlm.nih.gov/pubmed/32953518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-685 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|